Surgery

Mapping residual esophageal tumors—a glimpse into the future?

It's one of the first questions asked by many newly-diagnosed cancer patients—"What are my chances of beating this?" Often there is no clear answer, with survival rates differing widely depending on the cancer stage and ...

Cancer

ASH: A+CHP bests CHOP for peripheral T-cell lymphoma

(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone ...

page 1 from 23